Guselkumab 2 is named as a drug or biological intervention in 3 clinical trials in our USA, China, India and UK trial registers, none of which are currently recruiting. The lead sponsor is Janssen Research & Development, LLC. Registered phases: Phase 3 and Phase 2/3. Conditions studied include Crohn's Disease; Crohn Disease; Colitis, Ulcerative.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT05197049 | A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (ClinicalTrials.gov ↗) Crohn Disease |
Phase 3 | Active, closed |
| NCT05528510 | A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (ClinicalTrials.gov ↗) Colitis, Ulcerative |
Phase 3 | Active, closed |
| NCT03466411 | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease (ClinicalTrials.gov ↗) Crohn's Disease |
Phase 2/3 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Crohn's Disease | 1 |
| Crohn Disease | 1 |
| Colitis, Ulcerative | 1 |
| Lead sponsor | Trials |
|---|---|
| Janssen Research & Development, LLC | 3 |
| Register | Guselkumab 2 trials |
|---|---|
| Clinical trials in USA | 3 |
| Clinical trials in China | 3 |
| Clinical trials in India | 2 |
| Clinical trials in UK | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Guselkumab 2 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Guselkumab 2 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.